Irritable Bowel Syndrome Treatment Market Overview: 2026
The irritable bowel syndrome treatment market size was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. Signs & symptoms include abdominal pain, bloating, gas, cramping, and constipation or diarrhea. There are three types of irritable bowel syndrome such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Treatment of irritable bowel syndrome consist of stress relief, change in diet, proper medicines, and counselling. Medications available for the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used for the treatment of irritable bowel syndrome, which include dicyclomine, peppermint oil, and hyoscyamine.
Rise in geriatric population, increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, surge in level of stress, and unhealthy diet are the major factors that drive the growth of the irritable bowel syndrome treatment market. In addition, increase in awareness programs regarding the treatment and management of irritable bowel syndrome and surge in inclination toward IBS products that enhance therapeutic outcome are other factors that contribute toward the growth of the market. Furthermore, untapped potential offered by the developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment that treat all the symptoms of the IBS disorder and high competition among the key players related to pricing are expected to restrain the growth of the market.
Irritable Bowel Syndrome Treatment Market Segmentation
The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is bifurcated into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the irritable bowel syndrome treatment market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
Based on type, the market is segmented into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. The IBS with diarrhea (IBS-D) segment acquired the largest irritable bowel syndrome treatment market share in 2018. Furthermore, this segment is also expected to experience growth at the fastest rate during the forecast period, owing to increase in prevalence of gastrointestinal diseases such as constipation and diarrhea due to change in lifestyles, increase in geriatric population, surge in uptake of drugs such as linaclotide and lubiprostone, and rise in patient awareness toward the treatment of irritable bowel syndrome.
By Type
IBS With Diarrhea is projected as one of the most lucrative segment.
According to product, the rifaximin segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to increase in prevalence of irritable bowel syndrome, surge in adoption of the irritable bowel syndrome products, rise in geriatric population, increase in awareness toward irritable bowel syndrome and improved diagnosis, and development of technological advanced treatment products that has driven the demand for use of irritable bowel syndrome treatment market products worldwide.
By Product
Rifaximin holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Snapshot of Asia-Pacific Irritable Bowel Syndrome Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the irritable bowel syndrome treatment market, growth in awareness regarding the treatment of irritable bowel syndrome, and rise in adoption of irritable bowel syndrome treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contributes to the market growth. Some other factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are expected to drive the growth of the irritable bowel syndrome treatment market in Asia-Pacific.
By Geography
Asia-Pacific region would exhibit the highest CAGR of 9.9% during 2019-2026.
The key players profiled in this report include Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd.
Key Benefits for Stakeholders:
- The study provides an in-depth analysis of the irritable bowel syndrome treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers irritable bowel syndrome treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global irritable bowel syndrome treatment market growth.
Irritable Bowel Syndrome Treatment Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Product |
|
 By End User |
|
 By Region |
|
 Key Market Players | AstraZeneca plc, Ardelyx Inc., Novartis AG, Astellas Pharma Inc., Johnson & Johnson (McNeil Consumer Healthcare), Allergan plc, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Sebela Pharmaceuticals Inc., Abbott Laboratories |
Analyst Review
Irritable bowel syndrome treatment products relieves the patient from the gastrointestinal disorder symptoms and improves the quality of life. Diagnosis of irritable bowel syndrome is done by tests such as stool tests, blood tests, external imaging procedures, and endoscopic procedures. Treatment of irritable bowel syndrome include change in diet, stress relief, proper medicines, and counseling.
Increase in geriatric population, adoption of sedentary lifestyle, surge in level of stress and unhealthy diet, increase in prevalence of gastrointestinal diseases and disorders, rise in awareness programs for irritable bowel syndrome treatment significantly boost the growth of the irritable bowel syndrome treatment market. Moreover, launches of various developed pipeline drugs for the irritable bowel syndrome treatment and rise in awareness programs further boost the market growth. However, high competition among the key players related to pricing hinders the market growth.
North America is expected to remain dominant during the forecast period due to higher adoption of irritable bowel syndrome treatment products with increase in number of pipeline drugs, large presence of pharmaceutical, and R&D laboratories. In addition, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period due to developments in R&D and pharmaceutical sectors along with rise in demand for irritable bowel syndrome treatment products.
The market value of global irritable bowel syndrome treatment market was $1,070.5 million in 2018.
The forecast period is from 2019 to 2026.
The market value of global irritable bowel syndrome treatment market in 2019 is $1,159.3 million.
The adoption of irritable bowel syndrome treatment is expected to significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet majorly driving the market growth
The base year calculated in the report is 2018.
Yes, Allergan plc is profiled in the report.
Emerging countries of Asia-Pacific region are growing at a growth% of 9.9%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 9.8%, 11.0%, 9.1%, 10.6%, 9.4% respectively.
The North America market held a major share in the irritable bowel syndrome treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to development of technological advanced treatment products, increased adoption of irritable bowel syndrome treatment products for the treatment of gastrointestinal disorders, rise in patient awareness toward irritable bowel syndrome treatment, increase in incidences of gastrointestinal diseases, and rise in geriatric population are driving the irritable bowel syndrome treatment market in North America
Loading Table Of Content...
